NKTR logo

Nektar Therapeutics (NKTR) Long Term Liabilities

Annual Total Long Term Liabilities

$215.78 M
-$59.98 M-21.75%

31 December 2023

NKTR Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Long Term Liabilities

$191.50 M
-$14.82 M-7.18%

30 September 2024

NKTR Quarterly Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NKTR Long Term Liabilities Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-21.8%-17.0%
3 y3 years-37.6%-43.0%
5 y5 years-38.5%-59.6%

NKTR Long Term Liabilities High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 years-38.8%at low-45.7%at low
5 y5 years-38.8%at low-59.6%at low
alltimeall time-53.3%>+9999.0%-59.6%>+9999.0%

Nektar Therapeutics Long Term Liabilities History

DateAnnualQuarterly
Sept 2024
-
$191.50 M(-7.2%)
June 2024
-
$206.32 M(-4.9%)
Mar 2024
-
$216.90 M(+0.5%)
Dec 2023
$215.78 M(-21.8%)
$215.78 M(-6.5%)
Sept 2023
-
$230.76 M(-6.4%)
June 2023
-
$246.63 M(-5.5%)
Mar 2023
-
$261.00 M(-5.4%)
Dec 2022
$275.76 M(-21.8%)
$275.76 M(-3.2%)
Sept 2022
-
$284.79 M(-4.5%)
June 2022
-
$298.27 M(-4.1%)
Mar 2022
-
$310.95 M(-11.8%)
Dec 2021
$352.48 M(+2.0%)
$352.48 M(+5.0%)
Sept 2021
-
$335.73 M(+0.1%)
June 2021
-
$335.35 M(-0.9%)
Mar 2021
-
$338.42 M(-2.1%)
Dec 2020
$345.69 M(+58.5%)
$345.69 M(+63.7%)
Sept 2020
-
$211.19 M(-1.6%)
June 2020
-
$214.68 M(+0.3%)
Mar 2020
-
$214.04 M(-1.9%)
Dec 2019
$218.07 M(-37.8%)
$218.07 M(-54.0%)
Sept 2019
-
$474.23 M(+10.5%)
June 2019
-
$429.13 M(-1.0%)
Mar 2019
-
$433.25 M(+23.6%)
Dec 2018
$350.60 M(-3.9%)
$350.60 M(-0.1%)
Sept 2018
-
$350.89 M(-1.4%)
June 2018
-
$355.78 M(-0.6%)
Mar 2018
-
$357.81 M(-1.9%)
Dec 2017
$364.88 M(-10.7%)
$364.88 M(-10.0%)
Sept 2017
-
$405.35 M(+1.4%)
June 2017
-
$399.86 M(-1.3%)
Mar 2017
-
$405.22 M(-0.8%)
Dec 2016
$408.52 M(-5.2%)
$408.52 M(-1.9%)
Sept 2016
-
$416.64 M(-1.5%)
June 2016
-
$423.07 M(-0.7%)
Mar 2016
-
$426.21 M(-1.1%)
Dec 2015
$430.97 M(+26.3%)
$430.97 M(+113.2%)
Sept 2015
-
$202.09 M(-40.6%)
June 2015
-
$340.49 M(-1.7%)
Mar 2015
-
$346.46 M(+1.5%)
Dec 2014
$341.24 M(-19.9%)
$341.24 M(-2.3%)
Sept 2014
-
$349.13 M(-18.6%)
June 2014
-
$429.14 M(+2.8%)
Mar 2014
-
$417.51 M(-2.0%)
Dec 2013
$426.21 M(+14.5%)
$426.21 M(+21.0%)
Sept 2013
-
$352.37 M(-2.9%)
June 2013
-
$363.08 M(-1.1%)
Mar 2013
-
$367.30 M(-1.3%)
Dec 2012
$372.24 M(+179.4%)
$372.24 M(-1.2%)
Sept 2012
-
$376.65 M(+45.3%)
June 2012
-
$259.30 M(-0.9%)
Mar 2012
-
$261.55 M(+96.3%)
Dec 2011
$133.21 M(-63.6%)
$133.21 M(-3.7%)
Sept 2011
-
$138.25 M(-61.4%)
June 2011
-
$358.30 M(-1.7%)
Mar 2011
-
$364.36 M(-0.6%)
Dec 2010
$366.45 M(+14.5%)
$366.45 M(+17.9%)
Sept 2010
-
$310.70 M(-0.9%)
June 2010
-
$313.64 M(-1.4%)
Mar 2010
-
$318.11 M(-0.6%)
Dec 2009
$320.13 M
$320.13 M(+7.7%)
Sept 2009
-
$297.19 M(+0.0%)
DateAnnualQuarterly
June 2009
-
$297.08 M(-1.0%)
Mar 2009
-
$300.03 M(-0.7%)
Dec 2008
$302.01 M(-26.8%)
$302.01 M(-26.6%)
Sept 2008
-
$411.20 M(+1.0%)
June 2008
-
$407.03 M(-0.8%)
Mar 2008
-
$410.43 M(-0.5%)
Dec 2007
$412.57 M(+9.8%)
$412.57 M(+0.5%)
Sept 2007
-
$410.70 M(+4.4%)
June 2007
-
$393.46 M(+0.5%)
Mar 2007
-
$391.64 M(+4.2%)
Dec 2006
$375.80 M(-18.7%)
$375.80 M(-15.2%)
Sept 2006
-
$443.01 M(-0.9%)
June 2006
-
$447.05 M(+5.3%)
Mar 2006
-
$424.43 M(-8.2%)
Dec 2005
$462.15 M(+108.2%)
$462.15 M(-0.6%)
Sept 2005
-
$464.98 M(+113.1%)
June 2005
-
$218.19 M(-0.2%)
Mar 2005
-
$218.69 M(-1.5%)
Dec 2004
$221.93 M(-45.3%)
$221.93 M(-0.3%)
Sept 2004
-
$222.51 M(+1.9%)
June 2004
-
$218.32 M(-3.7%)
Mar 2004
-
$226.66 M(-44.1%)
Dec 2003
$405.74 M(+20.7%)
$405.74 M(-4.7%)
Sept 2003
-
$425.53 M(+2.6%)
June 2003
-
$414.93 M(+23.7%)
Mar 2003
-
$335.49 M(-0.2%)
Dec 2002
$336.20 M(-0.5%)
$336.20 M(-0.8%)
Sept 2002
-
$338.98 M(+0.6%)
June 2002
-
$337.00 M(-0.0%)
Mar 2002
-
$337.16 M(-0.2%)
Dec 2001
$337.73 M(+5.1%)
$337.73 M(-0.1%)
Sept 2001
-
$338.19 M(+0.9%)
June 2001
-
$335.12 M(+2.4%)
Mar 2001
-
$327.14 M(+1.8%)
Dec 2000
$321.45 M(+179.3%)
$321.45 M(+31.4%)
Sept 2000
-
$244.64 M(+0.0%)
June 2000
-
$244.57 M(-0.8%)
Mar 2000
-
$246.47 M(+114.1%)
Dec 1999
$115.10 M(+1864.5%)
$115.10 M(+1757.6%)
Sept 1999
-
$6.20 M(+3.7%)
June 1999
-
$5.97 M(+1.0%)
Mar 1999
-
$5.91 M(+0.9%)
Dec 1998
$5.86 M(+5.5%)
$5.86 M(+0.9%)
Sept 1998
-
$5.81 M(+0.9%)
June 1998
-
$5.75 M(+0.9%)
Mar 1998
-
$5.70 M(+2.6%)
Dec 1997
$5.55 M(+2677.5%)
$5.55 M(+1331.7%)
Sept 1997
-
$388.00 K(+139.5%)
June 1997
-
$162.00 K(-7.4%)
Mar 1997
-
$175.00 K(-12.5%)
Dec 1996
$200.00 K(-33.3%)
$200.00 K(0.0%)
Sept 1996
-
$200.00 K(0.0%)
June 1996
-
$200.00 K(-50.0%)
Mar 1996
-
$400.00 K(+33.3%)
Dec 1995
$300.00 K(-25.0%)
$300.00 K(+50.0%)
Sept 1995
-
$200.00 K(-33.3%)
June 1995
-
$300.00 K(-50.0%)
Mar 1995
-
$600.00 K(+50.0%)
Dec 1994
$400.00 K
$400.00 K(-20.0%)
Sept 1994
-
$500.00 K(0.0%)
June 1994
-
$500.00 K(-16.7%)
Mar 1994
-
$600.00 K

FAQ

  • What is Nektar Therapeutics annual total long term liabilities?
  • What is the all time high annual total long term liabilities for Nektar Therapeutics?
  • What is Nektar Therapeutics annual total long term liabilities year-on-year change?
  • What is Nektar Therapeutics quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Nektar Therapeutics?
  • What is Nektar Therapeutics quarterly long term liabilities year-on-year change?

What is Nektar Therapeutics annual total long term liabilities?

The current annual total long term liabilities of NKTR is $215.78 M

What is the all time high annual total long term liabilities for Nektar Therapeutics?

Nektar Therapeutics all-time high annual total long term liabilities is $462.15 M

What is Nektar Therapeutics annual total long term liabilities year-on-year change?

Over the past year, NKTR annual total long term liabilities has changed by -$59.98 M (-21.75%)

What is Nektar Therapeutics quarterly total long term liabilities?

The current quarterly long term liabilities of NKTR is $191.50 M

What is the all time high quarterly long term liabilities for Nektar Therapeutics?

Nektar Therapeutics all-time high quarterly total long term liabilities is $474.23 M

What is Nektar Therapeutics quarterly long term liabilities year-on-year change?

Over the past year, NKTR quarterly total long term liabilities has changed by -$39.27 M (-17.02%)